Rosacea

Rosacea is a chronic inflammatory disease of the central face — persistent redness, flushing, inflammatory papules and pustules, visible vessels, phymatous thickening (most visibly rhinophyma of the nose), and ocular involvement in a large minority — affecting roughly 5% of adults, most visibly the fair-skinned but demonstrably present and underdiagnosed in darker skin, where redness reads differently. The field's key reframe: the old subtype system implying progression through stages was replaced (2017 international consensus) by a phenotype model — patients have individual combinations of features, each treated on its own merits, and papulopustular disease does not march toward rhinophyma. Pathogenesis blends innate-immune hyperreactivity (cathelicidin pathway), neurovascular dysregulation, and an overpopulation of Demodex mites — which is why one disease answers to anti-inflammatories, vascular treatments and antiparasitics simultaneously.

Rosacea's cultural baggage does real damage. It is not acne — comedones are absent, and acne regimens (harsh cleansers, benzoyl peroxide at standard strengths) often inflame it. It is not caused by alcohol — the W.C. Fields nose slander persists in public imagination, attaching a drinker's stigma to a disease of immune and vascular biology; alcohol is one flare trigger among many (heat, sun, spice, stress, hot drinks), and rhinophyma occurs in teetotallers. And it is not poor hygiene or blushing temperament. Patients report the misattributions — especially the alcohol one — among the disease's heaviest burdens, alongside measured elevations in anxiety, depression and social avoidance. Correcting the story is part of the treatment.

For papules and pustules the ladder is well-trialled: topical ivermectin (targeting both inflammation and Demodex) leads the network meta-analyses, with metronidazole and azelaic acid as established alternatives and minocycline foam a newer entrant; moderate-to-severe disease adds oral sub-antimicrobial doxycycline — 40 mg modified-release, dosed below the antibiotic threshold as a pure anti-inflammatory, an approach that sidesteps resistance concerns and is licensed on exactly that logic. Refractory cases borrow low-dose isotretinoin off-label. Response takes weeks, maintenance is usually needed, and combination with the vascular and behavioural arms below is the norm rather than the exception.

Background erythema and flushing answer poorly to anti-inflammatories because they are vascular: topical alpha-agonists (brimonidine, oxymetazoline) constrict vessels for hours — genuinely useful for events, with a counselled minority experiencing rebound redness — while durable improvement of fixed erythema and telangiectasia comes from vascular lasers and intense pulsed light over several sessions, the standard of care cost and access permitting. Phymatous disease, once established, is structural: early inflammation may respond to isotretinoin, but developed rhinophyma is treated surgically or ablatively (electrosurgery, CO2 laser) with reliably transformative results — a fact many affected men are never told. Ocular rosacea — grittiness, blepharitis, recurrent styes — needs lid hygiene, topical or oral anti-inflammatories and, when significant, ophthalmology; it can precede the skin signs and threaten the cornea when missed.

Trigger management works when personalised: the classic list (sun, heat, alcohol, spice, stress, hot beverages, some cosmetics) varies enormously between patients, so a flare diary beats generic prohibition — most patients have two or three real triggers, not fifteen. Non-negotiables: daily broad-spectrum sunscreen (mineral formulations tolerate best), gentle cleansing, and barrier-supporting moisturisation — the rosacea barrier is measurably impaired and repairing it reduces reactivity. Comorbidity surveillance earns a mention without alarm: association studies link rosacea to cardiovascular and gastrointestinal conditions (including small-intestinal bacterial overgrowth in subsets, with H. pylori claims weaker), enough to justify ordinary risk-factor care rather than special screening. The course is chronic and relapsing; the realistic goal — near-clear skin with maintenance and known triggers avoided — is achievable for most.

Get the phenotype named: which of redness, flushing, papulopustules, phyma and eye disease you have determines everything, and mixed presentations get combined plans. For bumps: ivermectin cream first, 40 mg doxycycline added for moderate disease, judged at 8-12 weeks. For redness: expectations honestly set — creams and pills fade it modestly; alpha-agonist gels rent improvement, lasers buy it. For the nose changes: seek treatment early, and know that even established rhinophyma is fixable. For the eyes: mention grit and styes to whoever treats your skin. Keep a trigger diary before banning pleasures, wear the sunscreen daily — and retire the alcohol myth in your own circle: someone with rosacea will thank you.